Full Text
4087 GI/202 3 (1)
EXTRAORDINARY
PART II —Section 3 —Sub-section ( ii)
PUBLISHED BY AUTHORITY
(1) (2) (3) (4) (5) (6)
No. 2699] NEW DELHI, WEDNES DAY , JUNE 28, 2023/ASHADHA 7, 194 5
CG-DL-E-28062023-246857
(1) (2) (3) (4) (5) (6)
(1) (2) (3) (4) (5) (6)
16.95
17.84
19.57
20.67
13.63
14.60
(1) (2) (3) (4) (5) (6)
19.87
16.18
17.04
20.11
(1) (2) (3) (4) (5) (6)
19.00
12.50
15.00
16.04
16.98
19.11
(1) (2) (3) (4) (5) (6)
14.90
16.44
19.00
20.11
19.11
(1) (2) (3) (4) (5) (6)
(1) (2) (3) (4) (5) (6)
13.82
6.12
(6)
V
(4)
I
MINISTRY OF CHEMICAL S AND FERTILIZERS
(Department of Pharmaceuticals )
(NATIONAL PHARMACEUTI CAL PRICING AUTHORIT Y)
ORDER
New Delhi, the 28th June, 2023
S.O. 2821 (E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices
Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249 (E) dated 11th November , 2022
issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entrie s in columns (3), (4) and (5) thereof;
TABLE
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Ciprofloxacin &
Dexamethasone Eye
Drops Composition:
Ciprofloxacin Hydrochloride IP eq.
to Ciprofloxacin 0.3% w/v
Dexamethasone IP 0.1% w/v
Benzalkonium Chlorid Sodium IP
0.02% v/v (As preservative)
Sterile aqueous Vehicle q.s. 1 ml M/s Skymap
Healthcare Pvt. Ltd.
/M/s Healing Pharma
India Pvt. Ltd. 2.05
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Paracetamol,
Phenylephrine and
Chlorpheniramine
Drops Each ml (approximately 30
drops) contains :
Paracetamol IP 125mg
Phenylephrine Hydrochloride IP
2.5mg
Chlorpheniramine Maleate IP
1.0mg 1 ml M/s Cris Pharma (I)
Ltd.. / M/s Mankind
Prime Labs Pvt. Ltd. 4.15
Paroxetine
Controlled release &
Clonazepam
Capsules Each hard gelatine capsule
contains:
Paroxetine Hydrochloride IP eq. to
Paroxetine 25mg (As enteric coated
controlled release tablet)
&Clonazepam IP 0.5mg (as
immediate release tablet) 1 Capsule M/s Akums Drugs &
Pharmaceuticals
Limited / M/s Eris
Lifesciences Limited 15.81
Etoricoxib and
Paracetamol Tablets Each Film Coated tablet contains:
Etoricoxib IP 60 mg
Paracetamol IP 325 mg 1 Tablet M/s Pfizer Limited 8.99
5 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
500mg 1 Tablet M/s Intas
Pharmaceuticals Ltd. 8.97
6 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
1000mg 1 Tablet M/s Intas
Pharmaceuticals Ltd. 9.60
7 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
500mg 1 Tablet M/s Torrent
Pharmaceuticals Ltd. 8.90
8 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
1000mg 1 Tablet M/s Torrent
Pharmaceuticals Ltd. 9.50
9 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
500mg 1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd. 8.97
10 Linagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Linagliptin IP 2.5mg
Metformin Hydrochloride IP
1000mg 1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd. 9.60
11 Dapagliflozin,
Sitagliptin and
Metformin
Hydrochloride (as
Extended Release)
Tablets Each film coated tablet contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Sitagliptin Phosphate Monohydrate
eq. to Sitagliptin 100mg
Metformin Hydrochloride IP
500mg (as Extended Release) 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Wockhardt Limited
16.95
12 Dapagliflozin,
Sitagliptin and
Metformin Each film coated tablet contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Wockhardt Limited 17.84
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Hydrochloride (as
Extended Release)
Tablets 10mg
Sitagliptin Phosphate Monohydrate
eq. to Sitagliptin 100mg
Metformin Hydrochloride IP
1000mg (as Extended Release)
13 Dapagliflozin,
Sitagliptin and
Metformin
Hydrochloride (ER)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Sitaglip tin Phosphate Monohydrate
eq. to Sitagliptin 100mg
Metformin Hydrochloride IP
500mg (As an Extended -release
form) 1 Tablet M/s Mascot Health
Series Pvt. Ltd. / M/s
Aristo Pharmaceuticals
Pvt. Ltd.
19.57
14 Dapagliflozin,
Sitagliptin and
Metformin
Hydrochloride (ER)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Sitagliptin Phosphate Monohydrate
eq. to Sitagliptin 100mg
Metformin Hydrochloride IP
1000mg (As an Extended release
form ) 1 Tablet M/s Mascot Health
Series Pvt. Ltd. / M/s
Aristo Pharmaceuticals
Pvt. Ltd.
20.67
Dapagliflozin,
Sitagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Sitagliptin Phosphate Monohydrate
eq. to Sitagliptin 50mg
Metformin Hydrochloride IP
500mg 1 Tablet M/s Sun Pharma
Laboratories Limited
13.63
Dapagliflozin,
Sitagliptin and
Metformin
Hydrochloride
Tablets Each film coated tablet contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Sitagliptin Phosphate Monohydrate
eq. to Sitagliptin 50mg
Metformin Hydrochloride IP
1000mg 1 Tablet M/s Sun Pharma
Laboratories Limited
14.60
Dapagliflozin,
Vildagliptin (SR)
and Metform in
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Ravenbhel
Healthcare Pvt. Ltd. /
M/s Alkem
Laboratories Ltd. 18.76
Dapagliflozin,
Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin IP 100mg (As 1 Tablet M/s Ravenbhel
Healthcare Pvt. Ltd. /
M/s Alkem
Laboratories Ltd. 19.87
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release)
19 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin IP (As Sustained
release) 100 mg
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Eris Lifesciences
Limited 16.18
20 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each unc oated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin IP (As Sustained
release) 100mg
Metformin Hydrochloride IP
1000mg (as Sustained Release) 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Eris Lifescience s
Limited 17.04
21 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Emcure
Pharmaceuticals
Limited 16.18
22 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 1000mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Emcure
Pharmaceuticals
Limited 17.04
23 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 1000mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Mankind Pharma Ltd.
20.11
24 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metfo rmin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Mankind Pharma Ltd. 19.00
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Metformin Hydrochloride (as
Sustained Release) IP 500 mg
25 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Intas Pharmaceuticals
Ltd. 12.50
26 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 1000mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Intas Pharmaceuticals
Ltd. 15.00
27 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Zydus Healthcare
Limited 16.04
28 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
5mg
Vildagliptin (As Sustained release)
IP 100 mg
Metformin Hydrochloride (as
Sustained Release) IP 1000mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Zydus Healthcare
Limited 16.98
29 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Alemb ic
Pharmaceuticals
Limited 19.11
30 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Ravenbhel
Healthcare Pvt. Ltd. /
M/s Unison
Pharmaceuticals Pvt.
Ltd. 14.90
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
31 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each film coated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) I P 1000mg 1 Tablet M/s Ravenbhel
Healthcare Pvt. Ltd. /
M/s Unison
Pharmaceuticals Pvt.
Ltd. 16.44
32 Dapagliflozin,
Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Exemed
Pharmaceuticals / M/s
Torrent
Pharmaceuticals
Limited 19.00
Dapagliflozin,
Vildagliptin (SR)
and Metf ormin
Hydrochloride (SR)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release) 1 Tablet M/s Ex emed
Pharmaceuticals / M/s
Torrent
Pharmaceuticals
Limited 20.11
34 Dapagliflozin,
Vildagliptin (As
Sustained release)
and Metformin
Hydrochloride (as
Sustained Release)
Tablets Each uncoated bilayered tablet
contains:
Dapagliflozin Propanediol
Monohydrate eq. to Dapagliflozin
10mg
Vildagliptin (As Sustained release)
IP 100mg
Metformin Hydrochloride (as
Sustained Release) IP 500mg 1 Tablet M/s Mascot Health
Series Pvt. Ltd. / M/s
Alembic
Pharmaceuticals
Limited 19.11
35 Sitagliptin,
Pioglitazone and
Metformin
Hydrochloride
(Sustained Released)
Tablet Each uncoated bilayered tablet
contain s:
Sitagliptin Phosphate IP eq. to
Sitagliptin 100mg
Pioglitazone Hydrochloride IP eq.
to Pioglitazone 15 mg
Metformin Hydrochloride IP
500mg (Susta ined Release Form) 1 Tablet M/s Alkem Health
Science (A Unit of
Alkem Laboratories
Ltd.) / M/s Alkem
Laboratories Ltd 16.33
36 Sitagliptin,
Pioglitazone and
Metformin
Hydrochloride
(Sustained Released)
Tablet Each uncoated bilayered tablet
contains:
Sitagliptin Phosphate IP eq. to
Sitagliptin 100mg
Pioglitazone Hydrochloride IP eq.
to Pioglitazone 15 mg
Metformin Hydrochloride IP
1000mg (Sustained Release Form) 1 Tablet M/s Alkem Health
Science (A Unit of
Alkem Laboratories
Ltd.) / M/s Alkem
Laborato ries Ltd 17.69
37 Vildagliptin (SR) &
Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP (As Sustained
Release) 100mg 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Intas
Pharmaceuticals Ltd. 12.11
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Metformin Hydrochloride IP (As
Sustained Release) 500mg
38 Vildagliptin (SR) &
Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP (As Sustained
Release) 100mg
Metformin Hydrochloride IP (As
Sustained Rele ase) 500mg 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Torrent
Pharmaceuticals Ltd. 12.11
39 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Zydus Healthcare
Limited 12.28
40 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Lupin Limited 12.28
41 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Eris Lifesciences
Limited 12.28
42 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Cipla Limited 12.28
43 Vildagliptin (SR) &
Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP (As Sustained
Release) 100mg
Metformin Hydrochloride IP (As
Sustained Release) 1000mg 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Intas
Pharmaceuticals Ltd. 13.65
44 Vildaglipti n (SR) &
Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP (As Sustained
Release) 100mg
Metformin Hydrochloride IP (As
Sustained Release) 1000mg 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Torrent
Pharmac euticals Ltd. 13.65
45 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Lupin Limited 13.82
46 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Zydus Healthcare
Limited 13.82
Sl.
No. Name of the
Formulation /
Brand Name Strength Unit Manufacturer &
Marketing Company Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
Metformin Hydrochloride IP
1000mg (as Sustained Release)
47 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release)
1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Eris Lifesciences
Limited 13.82
48 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100 mg (As
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Cipla Limited 13.82
49 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each film coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
500mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Mankind Pharma
Ltd. 12.14
50 Vildagliptin (SR)
and Metformin
Hydrochloride (SR)
Tablets Each fi lm coated bilayered tablet
contains:
Vildagliptin IP 100mg (As
Sustained Release)
Metformin Hydrochloride IP
1000mg (as Sustained Release) 1 Tablet M/s Synokem
Pharmaceuticals Ltd. /
M/s Mankind Pharma
Ltd. 13.68
51 Zinc Sulfate
Monohydrate,
Sodium Citrate,
Potassium Chloride,
Sodium Chloride,
Dextrose Anhydrous
Sachet Each 4.4g sachet contains:
Zinc Sulfate Monohydrate IP
0.011g
Sodium Citrate IP 0.58g
Potassium Chloride IP 0.30g
Sodium Chloride IP 0.52g
Dextrose Anhydrous IP 2.70g Per
Sachet of
4.4 gm M/s Acme Diet Care
Pvt. Ltd. / M/s RPG
Life Sciences Ltd.
6.12
Note:
(a) The manufacturer of above -mentioned formulations i.e., ―new drug‖ under paragraph 2 (1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6 ) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form –V from date of
Notification as per paragraph 24 of the DPCO, 20 13 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / market er as mentioned
above i.e. wh o have applied for the same by submitting Form -I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory r equirements as laid down by the
Govt. under relevant statutes/ rules, including manufac turing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer /marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Ess ential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufactur er & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufactur er & Marketing Companies as specified in corresponding entries in Column ( 2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/2 46/114/2023/F F. No. 8( 114)/2023/D.P./NPPA -Div.-II]
MAHAVEER SAINI , Deputy Director (Pricing)
ubZ fnYyh] 28 जून, 2023
.—
4, 6, 10, 11, 14, 16,
,
.
(5)
(2)
(5)
(1) (2) (3) (4) (5)
V
(4)
(1)
II
I
II
III
II
IV
[
/
-II]
ORDER
New Delhi, the 28th June, 2023
S.O. 2822 (E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministr y of Chemicals and Fertilizers, the National
Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of
the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if an y, in respect of the
Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form &
strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl.
No. Nam e of the Scheduled
Formulation Dosage form and strength Unit Ceiling
Price (Rs.)
(1) (2) (3) (4) (5)
1 Dabigatran Capsule 110mg 1 Capsule 31.81
2 Dabigatran Capsule 150mg 1 Capsule 35.59
Note:
(a) All manufacturers of scheduled formulation, selling the b randed or generic or both the versions of
scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable)
so fixed and notified by the Government, shall revise the prices of all such formulations downward not
exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as
applicable, if any.
(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any,
shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer
in accordance with the ceiling price specified in column (5) of the above table as per provisions contained
in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in
Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPD MS and
submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries
on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in
the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing
manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified
under Schedule -II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall f urnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation s hall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) supers eded.
[PN/246/114/2023/F F. No. 8(114)/2023/D.P./NPPA -Div.-II]
MAHAVEER SAINI , Deputy Director (Pricing)
Uploaded by Dte. of Printing at Government of India Press, Ring R oad, Mayapuri, New Delhi -110064
and Published by the Controller of Publications, Delhi -110054.
Login to read full text